搜索头条
3
Researchers published late-stage clinical trial data today for the latest obesity drug, retatrutide—expected to be the most powerful formula yet—and the results appear in line with high expectations. Patients with obesity on the highest retatrutide dose lost an average of 25 perc
Ars Technica - All content ·
Pain and fatigue in rheumatoid arthritis can persist even after inflammation improves, with depression, poor sleep, obesity, smoking, and chronic pain potentially helping sustain symptoms. Researchers say identifying these hidden drivers could prevent unnecessary medication chang
All Top News -- ScienceDaily ·
As Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market.
Business News ·